tirofiban has been researched along with Heart Disease, Ischemic in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (24.44) | 18.2507 |
| 2000's | 31 (68.89) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO | 1 |
| Cuturello, D; Missiroli, B; Puddu, PE; Saladini, A; Schiariti, M | 1 |
| Heindl, B; Körner, M; Leibig, M; Ney, L | 1 |
| Boekstegers, P; Habazettl, H; Horstkotte, J; Krombach, F; Kupatt, C; Wichels, R | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Glaser, R; Herrmann, HC; Murphy, SA | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Moustapha, A; Rosales, OR; Salloum, J; Schroth, G; Sdringola, S; Smalling, RW | 1 |
| Goldschmidt-Clermont, PJ; Kandzari, DE; Mayes, CE; Phillips, HR | 1 |
| Brown, DL | 1 |
| Huynh, T; Snapinn, S; Theroux, P; Wan, Y | 1 |
| Adgey, AA; Manoharan, G | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Servoss, SJ; Snapinn, SM; Theroux, P; Wan, Y; Zhao, XQ | 1 |
| Ardissino, D; Brennan, DM; Buratti, S; Menozzi, A; Merlini, PA; Moliterno, DJ; Rossi, M; Topol, EJ | 1 |
| Barbieri, D; Ferrari, F; Ferrari, R; Guardigli, G; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Ducci, K; Falsini, G; Liistro, F | 1 |
| Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD | 1 |
| Berger, PB; Best, PJ; Chan, AW; DiBattiste, PM; Herrmann, HC; Kristensen, SD; Moliterno, DJ; Topol, EJ; White, J | 1 |
| Allie, AA; Allie, DE; Allie, SE; Barker, EA; Chaisson, G; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; McElderry, MW; Mitran, EV; Stagg, SJ; Vivekananthan, K; Walker, CM; Wyatt, CH | 1 |
| Chang, M; Dangas, G; Ellis, SG; Kao, J; Laufer, N; Mehran, R; Russell, ME; Stone, GW; Tannenbaum, MA; Teirstein, PS; Watkins, M | 1 |
| Huxtable, LM; Rakkar, AN; Tafreshi, MJ | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Brown, BG | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Adgey, AA | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F | 1 |
| Kleiman, NS; Ramanathan, A | 1 |
| Tcheng, JE | 2 |
| Harrington, RA | 1 |
| Dyke, CM | 1 |
| Ali, A; Grady, KJ; Patil, S; Schreiber, TL | 1 |
| Zidar, JP | 1 |
| De Rosa, V; Polimeno, S | 1 |
| Mak, KH; Moliterno, DJ | 1 |
| Berkowitz, SD | 1 |
| Goldberg, L; Mekel, J | 1 |
| Kondo, K | 1 |
| Jang, IK; Januzzi, JL; Sabatine, MS; Snapinn, S; Théroux, P | 1 |
| Chae, CU; Jang, IK; Januzzi, JL; Sabatine, MS | 1 |
| Merlini, PA; Rossi, ML | 1 |
| Albuquerque, A | 1 |
15 review(s) available for tirofiban and Heart Disease, Ischemic
| Article | Year |
|---|---|
The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Stents; Tirofiban; Tyrosine | 2002 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Risk Assessment; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.
Topics: Abciximab; Adrenal Cortex Hormones; Antibodies, Monoclonal; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Immunoglobulins, Intravenous; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Angioplasty; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1998 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine | 1999 |
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine | 1999 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists].
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
13 trial(s) available for tirofiban and Heart Disease, Ischemic
| Article | Year |
|---|---|
Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty; Eptifibatide; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Benefit of an early invasive management strategy in women with acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sex Factors; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2002 |
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Topics: Aged; Angina, Unstable; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Syndrome; Tirofiban; Tyrosine | 2003 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Topics: Acute Disease; Angina Pectoris; Coronary Artery Bypass; Fibrinolytic Agents; Follow-Up Studies; Heparin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Transfusion; Combined Modality Therapy; Coronary Stenosis; Double-Blind Method; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Coronary Stenosis; Creatine Kinase; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heparin; Humans; Intraoperative Complications; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Syndrome; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; Follow-Up Studies; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Risk; Risk Assessment; Syndrome; Tirofiban; Troponin T; Tyrosine | 2004 |
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Stenosis; Creatinine; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Drug Interactions; Eptifibatide; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Paclitaxel; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine | 1998 |
Elevation in serum troponin I predicts the benefit of tirofiban.
Topics: Acute Disease; Aged; Biomarkers; Coronary Disease; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Survival Rate; Tirofiban; Troponin I; Tyrosine | 2001 |
17 other study(ies) available for tirofiban and Heart Disease, Ischemic
| Article | Year |
|---|---|
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine | 2014 |
Traumatic dissection of a coronary artery: detection by multislice computed tomography and use of tirofiban as a reversible platelet inhibitor.
Topics: Accidents, Traffic; Aortic Dissection; Coronary Aneurysm; Coronary Angiography; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Thoracic Injuries; Tirofiban; Tomography, X-Ray Computed; Tyrosine; Young Adult | 2011 |
Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion.
Topics: Animals; Blood Platelets; Cell Adhesion; Chemotaxis, Leukocyte; Coronary Vessels; Endothelium, Vascular; Intercellular Adhesion Molecule-1; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Ischemia; Myocardial Reperfusion; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; Ventricular Function, Left | 2002 |
Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Catheters, Indwelling; Cohort Studies; Dose-Response Relationship, Drug; Equipment Failure; Female; Femoral Artery; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Retrospective Studies; Time Factors; Tirofiban; Tyrosine; Vascular Diseases | 2003 |
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Death, Sudden; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine | 2003 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Prospective Studies; Risk; Ticlopidine; Tirofiban; Troponin I; Tyrosine; Ultrasonography | 2004 |
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anticoagulants; Feasibility Studies; Female; Follow-Up Studies; Hirudins; Humans; Ischemia; Leg; Male; Myocardial Ischemia; Peptide Fragments; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Thrombin; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 1999 |
Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Fatal Outcome; Female; Hemoptysis; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombosis; Tirofiban; Tyrosine | 2000 |
[The use of BP IIb/IIIa inhibitors].
Topics: Fibrinolytic Agents; Humans; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2000 |
Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Confidence Intervals; Coronary Angiography; Double-Blind Method; Fibrinolytic Agents; Heparin; Humans; Incidence; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Probability; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2001 |
[Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |